West Pharmaceutical Services Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
West Pharmaceutical Services verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 13.8%, während die Gewinne der Branche Life Sciences jährlich um gewachsen und zwar um 11.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 9.8%. Die Eigenkapitalrendite von West Pharmaceutical Services beträgt 18.2% und die Nettomargen betragen 17.4%.
Wichtige Informationen
13.8%
Wachstumsrate der Gewinne
13.8%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 21.5% |
| Wachstumsrate der Einnahmen | 9.8% |
| Eigenkapitalrendite | 18.2% |
| Netto-Marge | 17.4% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29Aufschlüsselung der Einnahmen und Ausgaben
Wie West Pharmaceutical Services Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 2,876 | 500 | 342 | 69 |
| 30 Jun 24 | 2,877 | 525 | 349 | 70 |
| 31 Mar 24 | 2,929 | 569 | 355 | 69 |
| 31 Dec 23 | 2,950 | 593 | 354 | 68 |
| 30 Sep 23 | 2,927 | 559 | 299 | 66 |
| 30 Jun 23 | 2,866 | 519 | 326 | 63 |
| 31 Mar 23 | 2,884 | 552 | 319 | 61 |
| 31 Dec 22 | 2,887 | 586 | 316 | 59 |
| 30 Sep 22 | 2,909 | 631 | 377 | 56 |
| 30 Jun 22 | 2,929 | 686 | 352 | 56 |
| 31 Mar 22 | 2,881 | 684 | 362 | 55 |
| 31 Dec 21 | 2,832 | 662 | 356 | 53 |
| 30 Sep 21 | 2,681 | 613 | 340 | 52 |
| 30 Jun 21 | 2,523 | 519 | 310 | 51 |
| 31 Mar 21 | 2,326 | 423 | 308 | 48 |
| 31 Dec 20 | 2,147 | 346 | 301 | 47 |
| 30 Sep 20 | 2,037 | 312 | 291 | 44 |
| 30 Jun 20 | 1,945 | 286 | 297 | 41 |
| 31 Mar 20 | 1,888 | 261 | 277 | 40 |
| 31 Dec 19 | 1,840 | 242 | 273 | 39 |
| 30 Sep 19 | 1,792 | 230 | 262 | 39 |
| 30 Jun 19 | 1,767 | 229 | 259 | 39 |
| 31 Mar 19 | 1,745 | 219 | 258 | 41 |
| 31 Dec 18 | 1,717 | 207 | 256 | 40 |
| 30 Sep 18 | 1,711 | 155 | 257 | 40 |
| 30 Jun 18 | 1,677 | 151 | 256 | 39 |
| 31 Mar 18 | 1,627 | 133 | 248 | 38 |
| 31 Dec 17 | 1,599 | 151 | 243 | 39 |
| 30 Sep 17 | 1,566 | 190 | 245 | 39 |
| 30 Jun 17 | 1,544 | 176 | 242 | 39 |
| 31 Mar 17 | 1,535 | 182 | 243 | 38 |
| 31 Dec 16 | 1,509 | 144 | 238 | 37 |
| 30 Sep 16 | 1,487 | 138 | 241 | 37 |
| 30 Jun 16 | 1,454 | 102 | 238 | 37 |
| 31 Mar 16 | 1,426 | 85 | 246 | 36 |
| 31 Dec 15 | 1,400 | 96 | 243 | 34 |
| 30 Sep 15 | 1,390 | 94 | 240 | 32 |
| 30 Jun 15 | 1,401 | 123 | 241 | 33 |
| 31 Mar 15 | 1,411 | 133 | 228 | 35 |
| 31 Dec 14 | 1,421 | 127 | 229 | 37 |
| 30 Sep 14 | 1,414 | 119 | 230 | 39 |
| 30 Jun 14 | 1,400 | 115 | 230 | 39 |
| 31 Mar 14 | 1,376 | 108 | 232 | 39 |
| 31 Dec 13 | 1,368 | 112 | 235 | 38 |
Qualität der Erträge: WST hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: WSTDie aktuellen Gewinnspannen (17.4%) sind niedriger als im letzten Jahr (19.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: WSTIn den letzten 5 Jahren sind die Gewinne von 13.8% jährlich gestiegen.
Beschleunigtes Wachstum: WSTDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: WST hatte im vergangenen Jahr ein negatives Gewinnwachstum (-10.7%), was einen Vergleich mit dem Branchendurchschnitt Life Sciences (-4.7%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: WSTDie Eigenkapitalrendite des Unternehmens (18.2%) wird als niedrig angesehen.